These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 10357637)
1. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. Velasco M; Morán A; Téllez MJ N Engl J Med; 1999 Jun; 340(22):1765-6. PubMed ID: 10357637 [No Abstract] [Full Text] [Related]
2. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Carr A; Cooper DA Lancet; 1997 Apr; 349(9057):995-6. PubMed ID: 9100629 [No Abstract] [Full Text] [Related]
3. Ritonavir promotes increased growth in HIV-infected children. Paediatric AIDS Group of Switzerland. Nadal D; Steiner F; Cheseaux JJ; Rudin C AIDS; 1998 Dec; 12(17):2356-7. PubMed ID: 9863884 [No Abstract] [Full Text] [Related]
4. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Crommentuyn KM; Mulder JW; Sparidans RW; Huitema AD; Schellens JH; Beijnen JH Clin Infect Dis; 2004 Apr; 38(8):e73-5. PubMed ID: 15095234 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis coinfection and LPV/RTV. Carter M IAPAC Mon; 2004 Oct; 10(10):398. PubMed ID: 15801120 [No Abstract] [Full Text] [Related]
6. [Efficacy of ritonavir in HIV positive patients pretreated with nucleoside analogues]. Gómez-Cano M; Soriano V; Polo R; Valencia E; Adrados M; González-Lahoz J An Med Interna; 1998 Feb; 15(2):83-6. PubMed ID: 9542203 [TBL] [Abstract][Full Text] [Related]
7. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. Resino S; Bellón JM; Muñoz-Fernández MA; J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377 [No Abstract] [Full Text] [Related]
8. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination. Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672 [No Abstract] [Full Text] [Related]
10. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra). TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690 [No Abstract] [Full Text] [Related]
11. Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy. De Socio GV; Martinelli L; Zazzi M; Baldelli F Clin Infect Dis; 2008 Jun; 46(12):1938. PubMed ID: 18540815 [No Abstract] [Full Text] [Related]
12. Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill. Johnson M AIDS; 2006 Oct; 20(15):1987. PubMed ID: 16988525 [No Abstract] [Full Text] [Related]
13. FDA notifications. HIV-1 adult treatment guidelines are updated. AIDS Alert; 2006 Jun; 21(6):71. PubMed ID: 16795141 [No Abstract] [Full Text] [Related]
14. [Mollusca contagiosa in HIV-infected children receiving optimal antiretroviral therapy]. Horneff G; Wahn V Klin Padiatr; 2000; 212(2):83-4. PubMed ID: 10812559 [TBL] [Abstract][Full Text] [Related]
15. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520 [TBL] [Abstract][Full Text] [Related]